Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the world; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
In addition to addressing multiple sclerosis, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product targets a different but also widespread neurological issue: the temporary cognitive impairment and physiological discomfort caused by alcohol consumption.
The company’s dual-pronged attack on brain disorders highlights its commitment to addressing conditions that affect millions but have limited treatment options. With Lucid-MS aiming to modify the course of MS rather than just manage symptoms, and unbuzzd offering a novel approach to alcohol-related cognitive effects, Quantum BioPharma is positioning itself at the forefront of neurological innovation.
For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
